Overview

Staccato Prochlorperazine Thorough QT/QTc

Status:
Completed

Trial end date:
2007-12-01

Target enrollment:

Participant gender:

Summary

To assess the safety of Staccato Prochlorperazine on cardiac repolarization (QTc interval duration) at 2 dose levels compared to placebo in healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Alexza Pharmaceuticals, Inc.

Treatments:

Loxapine
Moxifloxacin
Prochlorperazine